CDK2 and melanoma: With loss of NF1 [18-21] and more recently an increase of CDK2 (in association with MITF) [22] in melanomas being involved in the resistance to BRAF-inhibitor (BRAFi) therapy, we next sought to investigate whether miR-514a might be involved in this process.